A new study found that a shorter time gap between melatonin production and sleep midpoints may be linked to longer survival among women with advanced breast cancer.
The phase III SERENA-6 clinical trial evaluated whether switching to treatment with camizestrant if an ESR1 mutation is detected during first-line treatment can help to slow cancer growth for patients...
Following a comprehensive national search, W. Kimryn Rathmell, MD, PhD, FASCO, former Director of the National Cancer Institute (NCI), has accepted the role of Chief Executive Officer (CEO) of The Ohi...
Researchers analyzed over 30,000 mammograms and found that specific breast texture patterns can predict cancer risk and missed diagnoses—even beyond breast density.